期刊文献+

体素内不相干运动成像联合扩散峰度成像对乳腺癌不同分子分型的预测价值

Predictive value of intravoxel incoherent motion and diffusion kurtosis imaging to breast cancer with different molecular subtypes
在线阅读 下载PDF
导出
摘要 目的:探讨体素内不相干运动(IVIM)成像联合扩散峰度成像(DKI)对乳腺癌分子分型的诊断价值。方法:选取经病理证实的乳腺癌患者244例,分为4个分子亚型(Luminal A型、Luminal B型、HER-2阳性型和三阴型),均行IVIM及DKI检查。分析不同分子分型乳腺癌的临床资料和真实扩散系数(D)、灌注相关扩散系数(D^(*))、灌注分数(f)、平均扩散峰度值(MK)和平均扩散率(MD),绘制ROC曲线比较其诊断效能。结果:244例中,Luminal A型32例,Luminal B型131例,HER-2阳性型36例,三阴型45例。Luminal A型的D^(*)值均小于其他分子分型(均P<0.01);三阴型的f值均高于其他分子分型(均P<0.01);Luminal B型的MD值小于HER-2阳性型及三阴型,而MK值大于HER-2阳性型及三阴型(均P<0.05)。D、D^(*)、f、MD及MK值对鉴别Luminal A/B型与非Luminal型有价值,其中IVIM成像的D^(*)值及DKI的MD值ROC曲线的AUC较大;且将IVIM成像与DKI联合后,AUC为0.752,诊断效能高于单一参数(Z=1.845~4.144,P=0.001~0.045)。D、D^(*)、MD及MK值对HER-2阳性型与非HER-2型有鉴别价值,其中IVIM成像的D值及DKI的MD值的AUC较大。D^(*)、f及MD值对鉴别三阴型与非三阴型有价值,三者联合后敏感度与准确度均高于单一参数。结论:IVIM成像联合DKI可用于乳腺癌分子分型的预测,有利于患者的个体化治疗。 Objective:To assess the predictive value of intravoxel incoherent motion(IVIM)and diffusion kurtosis imaging(DKI)in determining molecular subtypes expression in breast cancer.Methods:A total of 244 patients of breast cancer confirmed by pathology were collected,and they were divided into 4 molecular subtypes,Luminal A type,Luminal B type,HER-2-positive type and triple-negative type.IVIM and DKI scanning were performed in all patients.The values of true diffusion coefficient(D),perfusion-related diffusion coefficient(D^(*)),perfusion fraction(f),mean kurtosis(MK)and mean diffusivity(MD)were analyzed.The ROC curve was drawn to compare the diagnostic efficiency.Results:Among the 244 cases,32 cases were Luminal A type,131 cases were Luminal B type,36 cases were HER-2-positive type and 45 cases were triple-negative type.The D^(*)value of Luminal A type was lower than that of the other three types(P<0.01).The f value of triple-negative type was higher than that of the other three types(P<0.01).Luminal B type had a lower MD value and a higher MK value than the HER-2-positive type and triple-negative type(all P<0.05).The D,D^(*),f,MD and MK values were more valuable for distinguishing between Luminal A/B type and non-Luminal type,and the D^(*)and MD values had the larger AUCs.Combining the IVIM and DKI models,the AUC was 0.752,the diagnostic efficacy was higher than that of a single parameter(Z=1.845~4.144,P=0.001~0.045).The D,D^(*),MD and MK values were valuable for identifying HER-2-positive type and other molecular subtypes,and the D and MD values had the large AUCs.The D^(*),f and MD values were valuable for identifying triple-negative type and non-triple-negative type,and the sensitivity and accuracy of the combined three parameters were higher than those of a single parameter.Conclusion:IVIM combined with DKI can be used to predict the molecular subtype in breast cancer,which is beneficial for the individualized treatment.
作者 尹思远 邵凯 王唯伟 YIN Siyuan;SHAO Kai;WANG Weiwei(Department of Medical Imaging,Affiliated Hospital of Jining Medical University,Jining 272029,China)
出处 《中国中西医结合影像学杂志》 2024年第1期85-89,共5页 Chinese Imaging Journal of Integrated Traditional and Western Medicine
基金 山东省中医药科技项目(Q-2022132) 山东省医药卫生科技发展计划项目(202109010447) 济医附院医学英才培养计划项目(2022-yxyc-010)。
关键词 乳腺肿瘤 磁共振成像 体素内不相干运动 扩散峰度成像 Breast neoplasms Magnetic resonance imaging Intravoxel incoherent motion Diffusion kurtosis imaging
作者简介 通信作者:王唯伟,Email:1027070940@qq.com。
  • 相关文献

参考文献11

二级参考文献93

  • 1张兵,吴晶涛,叶靖,陆大军,袁为标,曹正业,沈力,徐圆.常规T2WI纹理特征与乳腺癌Ki-67表达水平的相关性研究[J].临床放射学杂志,2020,39(4):680-684. 被引量:11
  • 2原发性乳腺癌规范化诊疗指南(试行)[J].中国医学前沿杂志(电子版),2013,5(5):30-37. 被引量:44
  • 3Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of hu- man breast tumors[J]. Nature,2000,406(6797) : 747-752.
  • 4Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer sub- types, and survival in the Carolina breast cancer study[J]. JA- MA, 2006,295(21) : 2492-2502.
  • 5Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma [J]. Clin Cancer Res, 2004, 10(16) : 5367-5374.
  • 6Cheang MC, Chia SK, Voduc D, et al. Ki67 Index, HER2 sta- tus, and prognosis of patients with Luminal B breast cancer [ J ]. J Nati Cancer Inst,2009,101(10) : 731-750.
  • 7Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 1 O-year analysis of the ATAC trial [ J ]. Lancet Oncol, 2010, 11 (12): 1135-1141.
  • 8Huober J, Cole BF, Rabaglio M, et al. Symptoms of endocrine treatment and outcome in the BIG 1-98 study[J]. Breast Cancer Res Treat, 2014,143(1): 159-169.
  • 9van de Velde CJ, Rea D, Seynaeve C, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomized phase 3 trial[ J ]. Lancet, 2011,377(9762): 321-331.
  • 10Goldhirsch A, Wood WC, Coates AS, et al. Strategies for sub- types-dealing with the diversity of breast cancer: highlights of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 [J]. Ann Oncol, 2011,22 (8) : 1736-1747.

共引文献159

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部